Owlstone Medical secures $6.5 million to support development of breath-based diagnostics for infectious disease Post author: Post published: April 25, 2024 Post category:uncategorized Funding represents the first time the foundation has taken an equity position in a breath diagnostics company. You Might Also Like Oral-gut axis: How mouth bacteria impact your overall health July 24, 2024 Biognosys showcases next-gen multiomics innovations at ASMS 2026 June 26, 2026 Circulating exosomal microRNAs offer a non-invasive biomarker for MASLD April 17, 2026